BSX
Boston Scientific Corp is a developer, manufacturer and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally.
Boston Scientific Corporation (BSX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | B- (3.0) | D+ (1.7) | B+ (3.6) | C (2.3) | F (0.0) | C (2.2) |
| 2026-11-09 | B- (3.1) | D+ (1.7) | B+ (3.6) | C (2.2) | F (0.0) | C- (2.1) |
| 2026-11-04 | B- (3.1) | D+ (1.7) | B+ (3.8) | C- (2.1) | F (0.0) | C (2.2) |
| 2026-11-02 | B- (3.1) | D+ (1.7) | B+ (3.8) | C- (2.0) | F (0.0) | C- (2.1) |
| 2026-10-31 | B- (3.1) | C- (2.0) | B+ (3.7) | C- (2.1) | F (0.0) | C (2.2) |